For the first time in over 25 years (since the approval of oxybutynin in 1972), better medications are available for the overactive bladder ... [20] However, with the new spotlight and improved ...

Desmopressin is used in children with nocturnal enuresis, and it has recently shown some promise in the treatment of OAB in adults. Desmopressin is a synthetic analogue of vasopressin and thus ...

Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...

A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence ... agonist therapy used to treat overactive bladder with symptoms of urinary ...

For Science Quickly, I’m Rachel Feltman. I’m joined today by Marla Broadfoot, a freelance science journalist who recently covered the new drug for Scientific American. Marla, thank you so much ...

The FDA has approved Cobenfy, the first new schizophrenia treatment in over 30 years. Cobenfy helps reduce both positive and negative schizophrenia symptoms, with side effects compared to current ...

The trial aims to enrol 87 subjects with low-grade intermediate-risk non-muscle invasive bladder ... a new formulation of mitomycin that utilises UroGen’s RTGel platform technology. This ...

Botox is commonly used for beauty purposes but it can actually treat other conditions as well. Botulinum toxin, or Botox as ...

Our Photographers in Israel and Gaza Discuss the Images They Can’t Forget Seven New York Times journalists ... some widely held beliefs about the drug’s safety aren’t true → Megan Twohey ...

12) Teclistamab: Another drug already approved for marketing in the EU, J&J's Tecvayli is the first bispecific antibody targeted to BCMA for multiple myeloma, with ongoing phase 3 trials expected ...